Treatment and management of ascites and hepatorenal syndrome: An update

Therapeutic Advances in Gastroenterology

Volumn 8, Issue 2, 2015, Pages 83-100

  Lenz, Kurt ^a   Buder, Robert ^a   Voglmayr, Martin ^a   Kapun, Lisbeth ^b  

^a Konventhospital Barmherzige Bruder Linz   (Austria)

^b HFR Meyriez Murten ^*  (Switzerland)

Author keywords

acute kidney injury; ascites; diuretic therapy; hepatorenal syndrome

Indexed keywords

ALBUMIN; DIURETIC AGENT; HYPERTENSIVE FACTOR; TERLIPRESSIN;

ASCITES; GRANULOCYTE; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY PERFUSION; LIVER CIRRHOSIS; PARACENTESIS; PATHOPHYSIOLOGY; PERITONEAL FLUID; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SODIUM RESTRICTION; SPLANCHNIC BLOOD FLOW; TREATMENT INDICATION;

EID: 84922349505     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X14564673     Document Type: Review

References (126)

1. Acevedo J. Fernandez J. Prado V. Silva A. Castro M. Pavesi M. et al. (2013) Relative adrenal insufficiency in decompensated cirrhosis: relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology 58: 1757–1765.
2. Allesandria C. Ella C. Mezzabitta L. Risso A. Andrealli A. Spandre M. Morgando A. et al. (2011) Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded study. Digest Liver Dis 43: 881–886.
3. Angeli P. Dalla Pria M. de Bei E. Albino G. Caregaro L. Merkel C. et al. (1994) Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonacotemic cirrhotic patients with ascites. Hepatology 19: 72–79.
4. Angeli P. Fasolato S. Cavalllin M. Trotta E. Maresio G. Callegaro A. et al. (2009) Terlipressin given as continuous intravenous versus terlipressin given as intravenous boluses in the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis. J Hepatol 50(Suppl. 1): S73.
5. Angeli P. Fasolato S. Mazza E. Okolicsanyi L. Maresio G. Velo E. et al. (2010) Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 59: 98–104.
6. Angeli P. Morando F. (2010) Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepatic Med Evid Res 2: 87–98.
7. Angeli P. Volpin R. Gerunda G. Maresio G. Callegano A. Galieto A. et al. (1999) Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 29: 1690–1697.
8. Angeli P. Volpin R. Piovan D. Bortoluzzi A. Craighero R. Bottaro S. et al. (1998) Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 28: 937–943.
9. Angeli P. Wong F. Watson H. Gines P. (2006) Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 44: 1535–1542.
10. Arroyo V. (2013) A new method for therapeutic paracentesis: The automated low flow pump system. Comments in the context of the history of paracentesis. J Hepatol 58: 850–852.
11. Banares R. Nevens F. Larsen F. Jalan R. Albillos A. Dollinger M. et al. (2013) Extracorporeal albumin dialysis with the molecular adsorbend recirculating system in acute-on-chronic liver failure. The RELIEF trial. Hepatology 57: 1153–1162.
12. Baradarian R. Ramdhaney S. Chapalamadugu R. Skoczylas L. Wang K. Rivilis S. et al. (2004) Early intensive resuscitation of patients with upper gastrointestinal bleeding decreases mortality. Am J Gastroent 9: 619–622.
13. Bari K. Minano C. Shea M. Inayat I. Hasehm H. Gilles H. et al. (2012) The combination of octreotide and midodrine is not superior to albumin in preventin recurrence of ascites after large-volume paracentesis. Clin Gastroenterol Hepatol 10: 1169–1175.
14. Becker E. (2011) Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 17: 1237–1248.
15. Belcher J. Garcia-Tsao G. Sanyal A. Bhogal H. Lim J. Ansar N. et al. (2013) Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 57: 753–762.
16. Bellot P. Welker M. Soriano G. von Schaewen M. Appenrodt B. Wiest R. et al. (2013) Automated low flow pump systems for the treatment of refractory ascites: A multicenter safety and efficacy study. J Hepatol 58: 922–927.
17. Bennet W. Keeffe E. Melnyk C. Mahler D. Rösch D. Rösch J. et al. (1975) Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 135: 964–970.
18. Bernardi M. Serfadeo D. Trevisani F. Rusticali A. Gasbarrini G. (1985) Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 31: 189–193.
19. Bortoluzzi A. Ceolotto G. Gola E. Sticca A. Bova S. Morando F. et al. (2013) Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 57: 266–276.
20. Boyer T. Sanyal A. Garcia-Tsao G. Blei A. Carl D. Bexon A. et al. (2011) Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics. J Hepatol 55: 315–321.
21. Burke G. Cirocco R. Roth D. Fernandez J. Allouche M. Mardkou M. et al. (1993) Activated cytokine pattern in hepatorenal syndrome: Fall in levels after successful orthotopic liver transplantation. Transplant Proc 25: 1876–1877.
22. Cardenas A. Gines P. Marotta P. Czerwiec F. Oyuang J. Guevara M. et al. (2012) Tolvaptan an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 56: 571–578.
23. Cardoso J. Gautreau C. Jeyaraj P. Patrzalek D. Cherruau B. Vauvourdolle M. et al. (1994) Augmentation of portal blood flow improves function of human cirrhotic liver. Hepatology 19: 375–380.
24. Charron C. Caille V. Jardin F. Vieillard-Baron A. (2006) Echocardiographic measurement of fluid responsiveness. Curr Opin Crit Care 12: 249–254.
25. D'Amico G. Garcia-Tsao G. Pagliaro L. (2006) Natural history and prognostic indicators of survival in cirrhosis. J Hepatol 44: 217–231.
26. Decaux G. Vassart G. (2008) Non-peptide arginine vasopressin antagonists: the vaptanes. Lancet 371: 1624–1632.
27. de Souza V. Hadj-Aissa A. Dolomanova O. Rabilloud M. Rognant N. Lemoine S. et al. (2014) Creatinine-versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 59: 1522–1531.
28. Esler M. Kye D. (1998) Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst 72: 210–219.
29. Fagundes C. Gines P. (2012) Hepatorenal syndrome: A severe, but treatable cause of kidney failure in cirrhosis. Am J Kidney Dis 59: 874–885.
30. Fernandez J. Navasa M. Planas R. Montoliu S. Monfort D. Doriano G. et al. (2007) Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133: 818–827.
31. Francoz C. Prie D. Abdel Razek W. Moreau R. Mandot A. Belghitti J. et al. (2010) Inaccuracies of creatinine and creatinine based equations in candidates for liver transplantation with low creatinine: Impact on the model for endstage liver disease score. Liver Transplant 16: 1169–1177.
32. Funk G. Doberer D. Fuhrmann V. Holzinger U. Kitzberger R. Kneidinger N. et al. (2006) The acidifying effect of lactate is neutralized by the alkalinizing effect of hypoalbuminemia in non-paracetamol-induced acute liver failure. J Hepatol 45: 387–392.
33. Gane E. Deray G. Liaw Y. Lim S. Lai C. Rasenack J. et al. (2014) Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 146: 138–146.
34. Garcia-Martinez R. Caracenni P. Bernardi M. Gines P. Arroyo V. Jalan R. (2013) Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 58: 1836–1846.
35. Garcia-Tsao G. Chirag R. Antonella V. (2008) Acute kidney injury in cirrhosis. Hepatology 48: 2064–2077.
36. Gerbes A. Gülber V. Bilzer M. (1998) Endothelin and other mediators in the pathophysiology of portal hypertension. Digestion 59(Suppl. 2): 8–10.
37. Gianotti R. Cardenas A. (2014) Hyponatraemia and cirrhosis. Gastroenterol Rep 2: 21–26.
38. Gines P. Angeli P. Lenz K. Moller S. Moore K. Moreau R. (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53: 397–417.
39. Gines P. Arroyo V. Quintero E. Planas R. Bory F. Cabrera J. et al. (1987) Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 93: 234–241.
40. Gines P. Arroyo V. Vargas V. Planas R. Casafont F. Panés J. et al. (1991) Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 325: 829–835.
41. Gines A. Planas R. Angeli P. Guarner C. Salerno F. Ginès P. et al. (1995) Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 22: 124–131.
42. Gines P. Schrier R. (2009) Renal failure in cirrhosis. N Engl J Med 361: 1279–1290.
43. Gines P. Uriz J. Calahorra B. García-Tsao G. Kamath P. Ruiz-del-Arbol L. et al. (2002) Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 123: 1839–1847.
44. Gluud L. Christensen K. Christensen E. Krag A. (2010) Systemic review of randomized trials of vasoconstrictor drugs for hepatorenal syndrome. Hepatology 51: 576–584.
45. Guevara M. Gines P. Bandi C. Gilabert R. Sort P. Jimenez W. et al. (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28: 416–422.
46. Hennenberg M. Trebicka J. Sauerbruch T. Heller J. (2008) Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 57: 1300–1314.
47. Israelsen M. Gluud L. Krag A. (2014) Acute kidney injury and hepatorenal syndrome in cirrhosis. J Gastroenterol Hepatol. DOI: 10.1111/jgh.12709.
48. Jalan R. Bernardi M. (2013) Effective albumin concentration and cirrhosis mortality from concept to reality J Hepatol 59: 918–920
49. Jalan R. Mookerjee R. Cheshire L. William R. Davies N. (2007) Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol 46(Suppl. 1): S95.
50. Jalan R. Schnurr K. Mookerjee R. Sen S. Cheshire L. Hodges S. et al. (2009) Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 50: 555–564.
51. Kalambokis G. Pappas K. Baltayiannis G. Katsanou A. Tsianos E. (2010) Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia. Scand J Gastroenterol 45: 1509–1515.
52. Kew M. Varma R. Sampson D. Sherlock S. (1972) The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver. Gut 33: 14–20.
53. Kirchheim H. Ehmke H. (1994) Vasoactive hormones: modulators of renal function. Clin Invest 72: 685–687.
54. Kiszja-Kanowith M. Henriksen J. Hansen E. Moller S. Bendtsen F. (2004) Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 39: 486–492.
55. Kostreva D. Castaner A. Kampine J. (1980) Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 238: R390–R394.
56. Krag A. Bendtsen F. Burroughs A. Moller S. (2012) The cardiorenal link in advanced cirrhosis. Med Hypoth 79: 53–55.
57. Krag A. Bendtsen F. Mortensen C. Henriksen J. Moller S. (2010) Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol 22: 1085–1092.
58. Krag A. Moller S. Henriksen J. Holstein-Rathlou N. Larsen F. Bendtsen F. (2007) Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 46: 1863–1871.
59. Krag A. Wiest R. Albillos A. Gluud L. (2012) The window hypothesis: haemodynamic and nonhaemodynamic effects of ß-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 61: 967–969.
60. Laenaerts A. Codden T. Meunier J. Henry J. Ligny G. (2006) Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 44: 844–849.
61. Laenerts A. Coddon T. van Cauter J. Moukhaiber H. Meunier J. Ligny G. (1997) Treatment of refractory ascites with clonidine and spironolactone. Gastroenterol Clin Biol 21: 524–525.
62. Lang F. Tschernko E. Schulze E. Öttl I. Ritter M. Völkl H. et al. (1991) Hepatorenal reflex regulating kidney function. Hepatology 14: 590–594.
63. Lange M. Morelli A. Ertmer C. Koehler G. Bröking K. Hucklenbruch C. et al. (2007) Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28: 623–629.
64. Lebrec D. Giuily N. Hadengue A. Vilgrain V. Moreau R. Poynard T. et al. (1996) Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 25: 135–144.
65. Lenz K. (2005) Hepatorenal syndrome – is it hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction. Hepatology 42: 263–265.
66. Lenz K. Hörtnagl H. Druml W. Reither H. Schmid R. Schneeweiss B. et al. (1991) Ornipressin in the treatment of functional renal failure in decompensates liver cirrhosis. Gastroenterology 101: 1060–1067.
67. Le Veen H. Christoudias G. Ip M. Luft R. Flak G. Grosberg S. (1974) Peritoneo-venous shunting for ascites. Ann Surg 180: 580–591.
68. Levy M. Wexler M. (1987) Hepatic denervation alters first phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol 253: F664–F671.
69. Lodhia N. Kader M. Mayes T. Mantry P. Maliakkal B. (2009) Risk of contrast induced nephropathy in hospitalized patients with cirrhosis. World J Gastroenterol 15: 1459–1464.
70. Maddukuri G. Cai C. Munigala S. Mohammadi F. Zhang Z. (2014) Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. Dig Dis Sci 59: 471–481.
71. Mahmoodi K. Sohrabi B. Ilkhchooyi F. Malaki M. Khaniani M. Hemmati M. (2014). The efficacy of hydration with normal saline versus hydration with sodium bicarbonate in the prevention of contrast-induced nephropathy. Heart Views 15: 33–36.
72. Martin-Llahi M. Pepin M. Guevara M. Diaz F. Torre A. Monescillo A. et al. (2008) Terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134: 1352–1359.
73. Martinet O. Reis E. Mosimann F. (2000) Delayed hemoperitoneum following large-volume paracentesis in a patient with cirrhosis and ascites. Dig Dis Sci 45: 357–358.
74. Mathurin P. Louvert A. Duhamei A. Nahon P. Carbonell N. et al. (2013) Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis. A randomized trial. JAMA 310: 1033–1041.
75. McCormick P. Mistry P. Kaye G. Burroughs A. McIntyre N. (1990) Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 31: 204–207.
76. Mehta R. Kellum J. Shah S. Molitoris B. Ronco C. Warnock D. et al. (2007) Acute kidney injury network: report of an initiative to improve outcomes in kidney injury. Crit Care 11: R31.
77. Ming Z. Smyth D. Lautt W. (2002) Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 35: 167–175.
78. Mitzner S. Stange J. Klammt S. Risler T. Erley C. Bader B. et al. (2000) Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled trial. Liver Transplant 6: 277–286.
79. Moore K. (2013) Acute kidney injury in cirrhosis: A changing spectrum. Hepatology 57: 435–437.
80. Moore K. Aithal G. (2006) Guidelines on the management of ascites in cirrhosis. Gut 55(Suppl. 6): vi1–v12.
81. Moore K. Wong F. Gines P. Bernardi M. Ochs A. Salerno F. (2003) The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 38: 258–266.
82. Nadim M. Kellum J. Davenport A. Wong F. Davis C. Pannu N. et al. (2012) Hepatorenal syndrome: the 8th international conference of the acute dialysis initiative (ADQI) group. Crit Care 16: R23.
83. Nazar A. Pereira G. Guevara M. Martin-Llahi M. Pepin M. Marinelli M. et al. (2011) Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 55: 315–321.
84. Neri S. Pulvirent D. Malaguarnera M. Cosimo B. Bertino G. Ignaccolo L. et al. (2008) Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 53: 830–835.
85. Oettl K. Birner-Gruenberger R. Spindelmoeck W. Stueger H. Dorn L. Stadlbauer V. et al. (2013). Oxidative albumin damage in chronic liver failure. A relation to albumin binding capacity, liver dysfunction and survival. J Hepatol 59: 978–983.
86. Ortega R. Gines P. Uriz J. Cardenas A. Calahorra B. Las Heras D. et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized controlled study. Hepatology 36: 941–948.
87. Perez-Ayuso R. Arroyo V. Planas R. Gaya J. Bory F. Rimola A. et al. (1982) Randomized comparative study of efficacy of furosemide versus spironolactone in nonacezotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin–aldosterone system. Gastroenterology 84: 961–968.
88. Persson P. Ehmke H. Nafz B. Kirchheim R. (1990) Sympathetic modulation of renal autoregulation by carotid occlusion in conscious dog. Am J Physiol 258: F364–F370.
89. Peschl L. (1987) Klinische und experimentell Untersuchungen über die Wirkung von Dopamin auf die Hämodynamik und Funktion von Niere und Leber. Wien Klin Wochenschr 86(Suppl.): 1–33.
90. Pockros P. Reynolds T. (1986) Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 90: 1827–1833.
91. Restuccia T. Ortega R. Guevara M. Gines P. Alessandria C. Ozdogan O. et al. (2004) Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case control study. J Hepatol 40: 140–146.
92. Ripoli C. Groszmann R. Garcia-Tsao G. Grace N. Burroughs A. Planas R. et al. (2007) Hepatic venous gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133: 481–488.
93. Romanelli R. Villa G. Barletta G. Vizzuti F. Lanini F. Arena U. et al. (2006) Long term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 12: 1403–1407.
94. Rössle M. Ochs A. Gulberg V. Siegerstetter V. Holl J. Deibert P. et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342: 1701–1707.
95. Ruiz-del-Arbrol L. Nonescillo A. Arocena C. Valer P. Gines P. Moreira V. et al. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42: 439–447.
96. Runyon B. (2012) Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 57: 1651–1653.
97. Runyon B. Hoefs J. Morgan T. (1988) Ascitic fluid analysis in malignancy- related ascites. Hepatology 8: 1104–1109.
98. Ryckwaert F. Visolvy A. Fort A. Murat B. Richard S. et al. (2009) Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: Consequences on heart perfusion and performance. Crit Care Med 37: 876–881.
99. Salerno F. Gerbes A. Gines P. Wong F. Arroyo V. (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310–1318.
100. Salerno F. Merli M. Riggio O. Cazzaniga M. Valeriano V. Pozzi M. et al. (2004) Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40: 629–635.
101. Salerno F. Navickis R. Wilkes M. (2013) Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: A metanalysis of randomized trials. Clin Gastroenterol Hepatol 11: 123–130.
102. Santos J. Planas R. Pardo A. Durandez R. Cabre E. Morllas R. et al. (2003) Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 39: 187–192.
103. Sanyal A. Boyer T. Garcia-Tsao G. Regenstein F. Rossaro L. Appenrodt B. et al. (2008) A randomized prospective double-blind placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360–1368.
104. Sanyal A. Freedman A. Shiffman M. Purdum P. Luketic V. Cheatham A. (1994) Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 20: 46–55.
105. Sanyal A. Genning C. Reddy K. Wong F. Kowdley K. Benner K. et al. (2003) The North America study for the treatment of refractory ascites. Gastroenterology 124: 634–641.
106. Serste T. Francoz C. Durand F. Rautou P. Valla D. Moreau R. et al. (2010) Deleterious effects of betablockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52: 1017–1022.
107. Sharma P. Kumar A. Shrama B. Sarin S. (2008) An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103: 1689–1697.
108. Singh V. Dhungana S. Singh B. Vijayverghia R. Nain C. Sharma N. et al. (2012 a) Midodrine in patients with cirrhosis and refractory ascites: a randomized pilot study. J Hepatol 56: 348–354.
109. Singh V. Ghosh S. Singh B. Kumar P. Sharma N. Bhalla A. (2012 b) Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 56: 1293–1298.
110. Singh V. Singh A. Singh B. Vijayvergiya R. Sharma N. Ghai A. et al. (2013) Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. Am J Gastroenterol 108: 560–567.
111. Skagen C. Einstein M. Lucey M. Said A. (2009) Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 43: 680–685.
112. Solanki P. Chawla A. Garg R. Gupta R. Jain M. Sarin S. (2003) Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 18: 152–156.
113. Solis-Herruzo J. Duran A. Favela V. Castellano G. Madrid J. Munoz-Yaguem M. et al. (1987) Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 5: 167–173.
114. Somberg K. Riegler J. La Berge J. Doherty-Simor M. Bachetti P. Roberts J. et al. (1995) Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol 90: 549–555.
115. Sort P. Navas M. Arroyo V. Aldeguer X. Planas R. Ruiz-del-Arbol L. et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403–409.
116. Soulsby C. Madden A. Morgan M. (1997) The effect of dietary sodium restriction on energy and protein intake. Hepatology 26( Suppl. 382A): 1013.
117. Stadlbauer V. Wright G. Banaji M. Mukhopadhya A. Mookejee R. Moore K. et al. (2008) Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 134: 111–119.
118. Trawalé J. Paradis V. Rautou P. Francoz C. Escolano S. Sallée M. et al. (2010) The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 30: 725–732.
119. Tzamaloukas A. Malhotra D. Rosen B. Raj D. Murata G. Shapiro J. (2013) Principles of management of severe hyponatremia. J Am Heart Assoc 2 (4): e000240.
120. Umgelter A. Reindl W. Huber W. Schmid R. (2009) Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 35: 152–156.
121. Umgelter A. Wagner K. Reindl W. Luppa P. Geisler F. Huber W. et al. (2012) Renal and circulatory effects of large volume plasma expansion in patients with hepatorenals syndrome type 1. Ann Hepatology 11: 232–239.
122. Velez J. Nietert P. (2011) Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. Am J Kidney Dis 58: 928–938.
123. Witzke O. Baumann M. Patschan D. Patschan S. Mitchell A. Treichel U. et al. (2004) Which patients benefit from hemodialysis therapy in hepatorenal syndrome? J Gastroenterol Hepatol 19: 1369–1373.
124. Wong F. Massie D. Hsu P. Dudley F. (1994) Dose dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology 106: 658–663.
125. Wong F. Nadim M. Kellum J. Salerno F. Bellomo R. Gerbes A. et al. (2011). Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 60: 702–709.
126. Wong F. Pantea L. Sniderman K. (2004) Midodrine, octreotide, albumin and TIPS selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40: 55–64.